A Phase 2 study of Docetaxel and Bevacizumab as the second line treatment for patients with non-squamous non-small cell lung cancer previously treated with platinum-based chemotherapy.
- Conditions
- non-squamous non-small cell lung cancer
- Registration Number
- JPRN-UMIN000006641
- Lead Sponsor
- Kinki University Faculty of Medicine, Nara Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 41
Not provided
1. No prior treatment with Docetaxel and Bevacizumab 2.History of hemoptysis with 2.5mL per time or more. 3.Interstitial pneumonia or pulmonary fibrosis detectable on X ray. 4.massive pleural or pericardial effusion. 5. CNS metastasis 6. Patients with a concomitant or prior invasive malignancy who have had any evidence of the disease within the last 5 years 7. Patients with severe complications Unstable angina. cardiovascular disease, severe heart disease, heart failure within 3month. Uncontrollable diabetes mellitus and hypertension Active infection 8. In pregnancy, during breast feeding, or possibility of pregnancy. 9.The past history of severe allergic reactions 10. psychiatric patients 11. Any other medical condition that makes the patient unsuitable for inclusion in the study according to the opinion of the investigator.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Response Rate
- Secondary Outcome Measures
Name Time Method Safety, Progression Free Survival